GB1257841A - - Google Patents

Info

Publication number
GB1257841A
GB1257841A GB1257841DA GB1257841A GB 1257841 A GB1257841 A GB 1257841A GB 1257841D A GB1257841D A GB 1257841DA GB 1257841 A GB1257841 A GB 1257841A
Authority
GB
United Kingdom
Prior art keywords
ergocryptine
bromo
pharmaceutically acceptable
acid addition
addition salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GB1257841A publication Critical patent/GB1257841A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C07D519/02—Ergot alkaloids of the cyclic peptide type

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
GB1257841D 1968-05-31 1969-05-07 Expired GB1257841A (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH816868A CH507249A (de) 1968-05-31 1968-05-31 Verfahren zur Herstellung von 2-Brom-a-ergokryptin

Publications (1)

Publication Number Publication Date
GB1257841A true GB1257841A (enExample) 1971-12-22

Family

ID=4336202

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1257841D Expired GB1257841A (enExample) 1968-05-31 1969-05-07

Country Status (19)

Country Link
US (2) US3752814A (enExample)
AT (1) AT301765B (enExample)
BE (1) BE733799A (enExample)
BR (1) BR6909341D0 (enExample)
CA (1) CA953720A (enExample)
CH (1) CH507249A (enExample)
CS (1) CS163736B2 (enExample)
CY (1) CY780A (enExample)
DE (1) DE1926045C3 (enExample)
DK (1) DK124884B (enExample)
FI (1) FI49035C (enExample)
FR (1) FR2009737A1 (enExample)
GB (1) GB1257841A (enExample)
IT (1) IT7827515A0 (enExample)
MY (1) MY7500028A (enExample)
NL (1) NL151374B (enExample)
PL (1) PL80058B1 (enExample)
SE (1) SE341854B (enExample)
YU (1) YU33970B (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3920664A (en) * 1972-07-21 1975-11-18 Lilly Co Eli D-2-halo-6-alkyl-8-substituted ergolines and related compounds
US4199579A (en) * 1975-03-14 1980-04-22 Siphar S. A. Carbamates of 2-haloergolines and 2-haloergolenes and process for the preparation thereof
US4054660A (en) * 1975-04-14 1977-10-18 Eli Lilly And Company Method of inhibiting prolactin
CH619468A5 (enExample) * 1976-01-12 1980-09-30 Sandoz Ag
DE2750090A1 (de) * 1976-11-19 1978-06-01 Sandoz Ag Neue verabreichungsformen fuer organische verbindungen
YU39786B (en) * 1976-12-23 1985-04-30 Lek Tovarna Farmacevtskih Process for preparing 2-bromo-alfa-ergocriptine
IT1192260B (it) * 1977-07-05 1988-03-31 Simes Derivati di ergoline-2-tioeteri e loro solfossidi
YU216177A (en) * 1977-09-09 1984-02-29 Rudolf Rucman Process for preparing 2-bromo ergosine
IT1158162B (it) * 1977-12-22 1987-02-18 Sandoz Ag Composizioni farmaceutiche a base di derivati dell'ergolena e dell'ergolina
YU39849B (en) * 1978-09-26 1985-04-30 Lek Tovarna Farmacevtskih Process for preparing 2-bromo-ergolene and 2-bromo-ergoline compounds
DE3020895A1 (de) * 1979-06-12 1980-12-18 Sandoz Ag Ergopeptinderivate, verfahren zu deren herstellung sowie diese ergopeptinderivate enthaltende pharmazeutischen zusammensetzungen
DE3216869A1 (de) * 1982-05-03 1983-11-03 Schering AG, 1000 Berlin und 4709 Bergkamen Synergistische kombination mit zytostatischer wirkung
DE3216870A1 (de) * 1982-05-03 1983-11-03 Schering AG, 1000 Berlin und 4709 Bergkamen Pharmazeutische zubereitungen mit zytostatischer wirkung
JPS606815A (ja) * 1983-06-24 1985-01-14 Mitsutoyo Mfg Co Ltd 微動送り装置
DE3340025C2 (de) * 1983-11-03 1986-01-09 Schering AG, 1000 Berlin und 4709 Bergkamen Verfahren zur Herstellung von 2-Brom-8-ergolinyl-Verbindungen
CH666406A5 (de) * 1984-02-29 1988-07-29 Sandoz Ag Verfahren zur herstellung von mikrokapseln, welche bromokriptinmesylat als pharmakologischen wirkstoff enthalten.
HU193317B (en) * 1985-06-12 1987-09-28 Richter Gedeon Vegyeszet Process for producing 2-bromo-alpha-ergochristin
US4659715A (en) * 1986-03-07 1987-04-21 Louisiana State University And Agricultural And Mechanical College Method of inhibiting body fat stores
DE3722383A1 (de) * 1986-07-14 1988-01-28 Sandoz Ag Neue verwendung von bromocriptin
US5700800A (en) * 1988-05-10 1997-12-23 Ergo Science Incorporated Methods for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates with a prolactin stimulatory compound
US5344832A (en) * 1990-01-10 1994-09-06 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates
US5468755A (en) * 1988-05-10 1995-11-21 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Therapeutic process for the treatment of the pathologies of Type II diabetes
US5668155A (en) * 1988-05-10 1997-09-16 The General Hospital Corporation Administration of pirenzepine, methyl scopolamine and other muscarinic receptor antagonists for treatment of lipid metabolism disorders
US6004972A (en) * 1988-05-10 1999-12-21 The Board Of Supervisiors Of Louisiana State University And Agricultural And Mechanical College Therapeutic process for the treatment of the pathologies of type II diabetes
US5006526A (en) * 1988-10-17 1991-04-09 Louisiana State University Method of treating a vertebrate animal to reduce plasma triglycerides and cholesterol levels and to alleviate and prevent atherosclerosis
DE69022722T2 (de) * 1989-03-10 1996-05-02 Endorecherche Inc., Ste-Foy, Quebec Kombinationstherapie zur behandlung von estrogenempfindlichen erkrankungen.
CA2030174C (en) * 1990-01-10 1996-12-24 Anthony H. Cincotta Process for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hypoglycemia in vertebrates
US5416090A (en) * 1991-01-31 1995-05-16 Eli Lilly And Company Method of treating inflammation
IL112106A0 (en) * 1993-12-22 1995-03-15 Ergo Science Inc Accelerated release composition containing bromocriptine
US5817751A (en) * 1994-06-23 1998-10-06 Affymax Technologies N.V. Method for synthesis of diketopiperazine and diketomorpholine derivatives
US5792748A (en) * 1995-06-07 1998-08-11 The General Hospital Corporation Method for inhibiting neoplastic disease in mammals
DK0910365T3 (da) * 1996-05-01 2003-10-20 Harvard College Væksthæmning og udslettelse af faste tumorer ved at anvende en prolactinmodulator og en fotosensibilisator
US20010016582A1 (en) 1997-04-28 2001-08-23 Anthony H. Cincotta Method and composition for the treatment of lipid and glucose metabolism disorders
US5874589A (en) * 1997-07-18 1999-02-23 Glaxo Wellcome, Inc. Methods for synthesizing diverse collections of tetramic acids and derivatives thereof
US7771746B2 (en) * 1999-12-03 2010-08-10 Polichem Sa Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof
US6548484B1 (en) 2000-04-12 2003-04-15 International Medical Innovations, Inc. Pharmaceutical dopamine glycoconjugate compositions and methods of their preparation
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
US20060063803A1 (en) * 2004-09-23 2006-03-23 Pfizer Inc 4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds
ATE439347T1 (de) * 2004-11-23 2009-08-15 Warner Lambert Co 7-(2h-pyrazol-3-yl)-3,5-dihydroxy-heptansäure- derivate als hmg-co-a-reductase-inhibitoren zur behandlung von lipidemia
US8283312B2 (en) * 2005-02-04 2012-10-09 The Research Foundation Of State University Of New York Compositions and methods for modulating body weight and treating obesity-related disorders
WO2006099877A1 (en) * 2005-03-24 2006-09-28 Atef Mohammed Mostafa Darwish Rectal and vaginal suppositories containing bioadhesive bromocriptine and poloxamer
JP2009503050A (ja) * 2005-08-04 2009-01-29 ファイザー・リミテッド ピペリジノイル−ピロリジンおよびピペリジノイル−ピペリジン化合物
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
BRPI0708264A2 (pt) * 2006-02-23 2011-05-24 Pfizer Ltd piperidinilpirrolidinas agonistas do receptor tipo 4 de melanocortina
US8383660B2 (en) 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
CN101583593A (zh) 2006-11-13 2009-11-18 辉瑞产品公司 二芳基、二吡啶基和芳基-吡啶基衍生物及其用途
KR20090083477A (ko) * 2006-11-20 2009-08-03 그렌마크 파머수티칼스 에스. 아. 스테아로일-ＣｏＡ 불포화효소 저해제인 아세틸렌 유도체
EP2094643B1 (en) 2006-12-01 2012-02-29 Bristol-Myers Squibb Company N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
WO2009037542A2 (en) 2007-09-20 2009-03-26 Glenmark Pharmaceuticals, S.A. Spirocyclic compounds as stearoyl coa desaturase inhibitors
JP5328244B2 (ja) * 2008-07-07 2013-10-30 株式会社ニュージェン・ファーマ 筋萎縮性側索硬化症治療剤
MX2011001405A (es) * 2008-08-06 2011-03-21 Pfizer Ltd Compuestos de diazepina y diazocano como agonistas de mc4.
TWI537274B (zh) 2011-03-14 2016-06-11 橘生藥品工業股份有限公司 新穎之八氫噻吩并喹啉衍生物、含有其之醫藥組成物及該等之用途
US9585885B2 (en) 2012-12-10 2017-03-07 Kissei Pharmaceutical Co., Ltd. Substituted pyrido[2,3-g]quinazolines as dopamine D2 receptor agonists
WO2017184875A1 (en) * 2016-04-20 2017-10-26 Veroscience Llc Composition and method for treating metabolic disorders
CN110944639A (zh) 2017-06-28 2020-03-31 国立大学法人京都大学 用于预防和/或治疗阿尔茨海默病的药剂
PL3697418T3 (pl) 2017-10-18 2025-02-03 Veroscience Llc Polepszone preparaty bromokryptyny
WO2021061818A1 (en) 2019-09-23 2021-04-01 Veroscience Llc Method for inducing tumor regression

Also Published As

Publication number Publication date
FI49035B (enExample) 1974-12-02
BR6909341D0 (pt) 1973-02-08
NL6907038A (enExample) 1969-12-02
SE341854B (enExample) 1972-01-17
CS163736B2 (enExample) 1975-11-07
IT7827515A0 (it) 1978-09-11
FR2009737A1 (enExample) 1970-02-06
DE1926045C3 (de) 1978-09-21
FI49035C (fi) 1975-03-10
DK124884B (da) 1972-12-04
MY7500028A (en) 1975-12-31
CY780A (en) 1975-03-01
PL80058B1 (enExample) 1975-08-30
DE1926045A1 (de) 1969-12-04
YU133669A (en) 1978-02-28
US3752888A (en) 1973-08-14
NL151374B (nl) 1976-11-15
US3752814A (en) 1973-08-14
AT301765B (de) 1972-09-25
CA953720A (en) 1974-08-27
DE1926045B2 (de) 1978-01-12
CH507249A (de) 1971-05-15
YU33970B (en) 1978-09-08
BE733799A (enExample) 1969-12-01

Similar Documents

Publication Publication Date Title
GB1257841A (enExample)
GB1531092A (en) Carboxylic esters of substituted p-phenyl phenols and their use in liquid crystal cells
ES454747A1 (es) Un metodo para preparar compuestos de aminotetralol.
GB1309679A (en) Substituted sulphonanilides
GB1490486A (en) 4-imino-1,3-diazobicyclo-(3.1.0)hexan-2-one
GB1256723A (enExample)
GB1177445A (en) Ionone Derivatives and Process therefor
GB1434320A (en) Process for formylating organic basic nitrogen compounds
GB1167097A (en) Guanidine Derivatives
GB1361779A (en) Vincamine salt and its use as a pharmaceutical composition
GB1161093A (en) 1,2,5-Thiadiazole Derivatives
GB1291687A (en) A method for the production of formylnitrile derivatives
GB1136497A (en) Process for the preparation of 2-substituted cyclopentane- and cyclohexane-1,3-diones
GB1356406A (en) Indole derivatives
GB1261169A (en) Process for the preparation of n-(4-chlorophenylthiomethyl)-phthalimide
GB1153487A (en) Carboxymethyldithiocarbarmic Acids
GB1385563A (en) Aminophthalazine derivatives and pharmaceutical uses thereof
GB1306820A (en) Derivatives of the kallikrein-trypsin inhibitor their preparation and use as pharmaceuticals
GB1172554A (en) Bis-Thiosemicarbazones and a process for their manufacture
GB1207116A (en) Morphanthridine derivatives
GB1489784A (en) Pharmaceutically active substituted keto-acid derivatives
GB1235348A (en) Pyridine carboxylic acid amides
GB1266430A (enExample)
GB1230351A (enExample)
GB1218820A (en) N-imidazolinyl-benzal hydrazones, their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
PS Patent sealed [section 19, patents act 1949]
429H Application (made) for amendment of specification now open to opposition (sect. 29/1949)
429D Case decided by the comptroller ** specification amended (sect. 29/1949)
746B Proceeding under section 46(3) patents act 1977
746B Proceeding under section 46(3) patents act 1977
PE20 Patent expired after termination of 20 years